CompletedNCT02298075
Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Principal Investigator
- Maria Gabriella MazzucconiPoliclinico Umberto I, Hematology Department.
- Intervention
- Eltrombopag(drug)
- Enrollment
- 148 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2019
Study locations (13)
- S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti, Asti, Italy
- Istituto di Ematologia "Lorenzo e A. Seragnoli", Bologna, Italy
- Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi, Catania, Italy
- Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano, Florence, Italy
- Clinica Medica III - Padiglione ex isolamento - Azienda Ospedale Università San Martino, Genova, Italy
- ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy
- Azienda Ospedaliera "S.Gerardo", Monza, Italy
- Ematologia - Ospedale San Carlo, Potenza, Italy
- Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy
- Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy
- U.O.C. Ematologia - Ospedale S. Eugenio, Rome, Italy
- Università degli studi "Sapienza" di Roma, Rome, Italy
- Ematologia - Dipartimento di Medicina Clinica e Sperimentale, Sassari, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02298075 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation